Cargando…

Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and HRQOL in a well-documented clinical cohort during their last two years o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., Saarto, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247520/
https://www.ncbi.nlm.nih.gov/pubmed/30458739
http://dx.doi.org/10.1186/s12890-018-0738-x
_version_ 1783372492324208640
author Rajala, K.
Lehto, J. T.
Sutinen, E.
Kautiainen, H.
Myllärniemi, M.
Saarto, T.
author_facet Rajala, K.
Lehto, J. T.
Sutinen, E.
Kautiainen, H.
Myllärniemi, M.
Saarto, T.
author_sort Rajala, K.
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and HRQOL in a well-documented clinical cohort during their last two years of life. METHODS: In April 2015, we sent the Modified Medical Research Council Dyspnea Scale (MMRC), the modified Edmonton Symptom Assessment Scale (ESAS) and a self-rating HRQOL questionnaire (RAND-36) to 300 IPF patients, of which 247 (82%) responded. Thereafter, follow-up questionnaires were sent every six months for two years. RESULTS: Ninety-two patients died by August 2017. Among these patients, HRQOL was found to be considerably low already two years before death. The most prominent declines in HRQOL occurred in physical function, vitality, emotional role and social functioning (p < 0.001). The proportion of patients with MMRC scores ≥3 increased near death. Breathlessness and fatigue were the most severe symptoms. Symptom severity for the following symptoms increased significantly and reached the highest mean scores during the last six months of life (numeric rating scale/standard deviation): breathlessness (7.1/2.8), tiredness (7.0/2.3), dry mouth (6.0/3.0), cough (5.8/2.9), and pain with movement (5.0/3.5). CONCLUSIONS: To our knowledge this is the first study demonstrating, that IPF patients experience remarkably low HRQOL already two years before death, especially regarding physical role. In addition, they suffer from severe breathlessness and fatigue. Furthermore, physical, social and emotional wellbeing deteriorate, and symptom burden increases near death. Regular symptom and HRQOL measurements are essential to assess palliative care needs in patients with IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-018-0738-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6247520
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62475202018-11-26 Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life Rajala, K. Lehto, J. T. Sutinen, E. Kautiainen, H. Myllärniemi, M. Saarto, T. BMC Pulm Med Research Article BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and HRQOL in a well-documented clinical cohort during their last two years of life. METHODS: In April 2015, we sent the Modified Medical Research Council Dyspnea Scale (MMRC), the modified Edmonton Symptom Assessment Scale (ESAS) and a self-rating HRQOL questionnaire (RAND-36) to 300 IPF patients, of which 247 (82%) responded. Thereafter, follow-up questionnaires were sent every six months for two years. RESULTS: Ninety-two patients died by August 2017. Among these patients, HRQOL was found to be considerably low already two years before death. The most prominent declines in HRQOL occurred in physical function, vitality, emotional role and social functioning (p < 0.001). The proportion of patients with MMRC scores ≥3 increased near death. Breathlessness and fatigue were the most severe symptoms. Symptom severity for the following symptoms increased significantly and reached the highest mean scores during the last six months of life (numeric rating scale/standard deviation): breathlessness (7.1/2.8), tiredness (7.0/2.3), dry mouth (6.0/3.0), cough (5.8/2.9), and pain with movement (5.0/3.5). CONCLUSIONS: To our knowledge this is the first study demonstrating, that IPF patients experience remarkably low HRQOL already two years before death, especially regarding physical role. In addition, they suffer from severe breathlessness and fatigue. Furthermore, physical, social and emotional wellbeing deteriorate, and symptom burden increases near death. Regular symptom and HRQOL measurements are essential to assess palliative care needs in patients with IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-018-0738-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-20 /pmc/articles/PMC6247520/ /pubmed/30458739 http://dx.doi.org/10.1186/s12890-018-0738-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rajala, K.
Lehto, J. T.
Sutinen, E.
Kautiainen, H.
Myllärniemi, M.
Saarto, T.
Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title_full Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title_fullStr Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title_full_unstemmed Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title_short Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
title_sort marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247520/
https://www.ncbi.nlm.nih.gov/pubmed/30458739
http://dx.doi.org/10.1186/s12890-018-0738-x
work_keys_str_mv AT rajalak markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife
AT lehtojt markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife
AT sutinene markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife
AT kautiainenh markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife
AT myllarniemim markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife
AT saartot markeddeteriorationinthequalityoflifeofpatientswithidiopathicpulmonaryfibrosisduringthelasttwoyearsoflife